A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis

A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis

Abstract Background Giant cell arteritis (GCA) is primarily treated with glucocorticoids (GCs), which have substantial toxicity. Tocilizumab, an interleukin-6-receptor inhibitor (IL-6Ri), showed beneficial effects in GCA, leading to its approval. This study investigated the efficacy and safety of sa...

Full description

Bibliographic Details
Main Authors: Wolfgang A. Schmidt, Bhaskar Dasgupta, Jennifer Sloane, Angeliki Giannelou, Yuqing Xu, Sebastian H. Unizony, Sarah L. Mackie, Miguel A. Gonzalez-Gay, Robert Spiera, Kenneth J. Warrington, Peter M. Villiger, Michael C. Nivens, Bolanle Akinlade, Yong Lin, Frank Buttgereit, John H. Stone
Format: Article
Language:English
Published: BMC 2023-10-01
Series:Arthritis Research & Therapy
Subjects:
Sarilumab
Giant cell arteritis
Glucocorticoids
Interleukin-6
Sustained remission
Online Access:https://doi.org/10.1186/s13075-023-03177-6

Internet

https://doi.org/10.1186/s13075-023-03177-6

Similar Items